Form 4: CalciMedica Officer Michael J. Dunn Reports Stock Option Grant

Michael J. Dunn, President and COO of CalciMedica, reports the acquisition of employee stock options.

Summary

• Michael J. Dunn, President and COO of CalciMedica, filed a Form 4 with the SEC.
• The filing reports the grant of employee stock options to Dunn on April 23, 2025.
• Dunn acquired options to purchase 125,000 shares of CalciMedica common stock at an exercise price of $1.53 per share.
• The options vest in equal monthly installments over a four-year period, beginning March 26, 2025, with 1/48th of the shares vesting each month.
• The options expire on April 22, 2035.
• Following the reported transaction, Dunn directly owns options for 125,000 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of four years with monthly installments is a typical arrangement to incentivize long-term performance.
• Comparable companies in the biotech industry, such as Amgen or Gilead, also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting ownership if the options are exercised.
• The grant incentivizes the executive to improve company performance, which could benefit shareholders.

Key Dates

Keywords

Form 4, Stock Options, CalciMedica, Officer, Michael J. Dunn, Beneficial Ownership